Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery.
Daptomycin (Cubicin) is a branched cyclic lipopeptide antibiotic of nonribosomal origin and the prototype of the acidic lipopeptide family. It was approved in 2003 for the nontopical treatment of skin structure infections caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and in 2006 for the treatment of bacteremia. Understanding the ribosome-independent biosynthesis of daptomycin assembly will provide opportunities for the generation of daptomycin derivatives with an altered pharmaceutical spectrum to address upcoming daptomycin-resistant pathogens. Herein, the structural properties of daptomycin, its biosynthesis, recent efforts for the generation of structural diversity, and its proposed mode of action are discussed.
Department of Chemistry/Biochemistry, Philipps-University Marburg, Hans-Meerwein-Strasse, 35043 Marburg, Germany.
Lars
L
Robbel
Mohamed A
MA
Marahiel
D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000737:chemistry / Q000494:pharmacology; D001419:Bacteria / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D017576:Daptomycin / Q000096:biosynthesis* / Q000737:chemistry / Q000494:pharmacology; D005818:Genetic Engineering; D012270:Ribosomes
D000900:Anti-Bacterial Agents; D017576:Daptomycin